Cite
HARVARD Citation
Su, B. et al. (2022). Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. Journal of infection. 85 (3), pp. 334-363. [Online].